Optimal treatment of drug resistant hypertension.

Trial Profile

Optimal treatment of drug resistant hypertension.

Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Doxazosin (Primary) ; Bisoprolol; Spironolactone
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms PATHWAY-2
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2016 Results published in the Annals of Internal Medicine
    • 26 Jul 2015 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top